Abstract
In heart failure (HF) a main factor in reduced contractility is reduced SR Ca 2+ content and reversed force-frequency response (FFR), ie, from positive to negative. Our arrhythmogenic rabbit HF model exhibits decreased contractility mainly due to an increase in Na/Ca exchange (NCX) activity (with only modest decrease in SR Ca 2+ -ATPase (SERCA) function), similar to many end-stage HF patients. Here we test whether phospholamban (PLB) inhibition using a dominant-negative mutant PLB adenovirus (K3E/R14E, AdPLB-dn, with β-galactosidase adenovirus as control) could enhance SERCA function and restore Ca 2+ transients and positive FFR in ventricular myocytes from these HF rabbits. HF myocytes infected with AdPLB-dn (versus control) had enhanced Ca 2+ transient amplitude (2.0±0.1 versus 1.6±0.05 F/F o at 0.5 Hz, P 2+ transients declined faster in AdPLB-dn versus Adβgal myocytes (RT 50% : 317±29 versus 551±90 ms at 0.5 Hz, P 2+ load (3.5±0.3 versus 2.6±0.2 F/F o at 0.5 Hz, P 2+ load. This approach could enhance contractile function in failing hearts of various etiologies, even here where reduced SERCA activity is not the main dysfunction.

This publication has 10 references indexed in Scilit: